Novo Nordisk said lower-dose strengths of Wegovy will be limited as it tries to ramp up production to meet the surge in demand for the weight loss drug.
warned Thursday that there will be continued supply constraints for Wegovy in the U.S. as it struggles to meet demand and that some patients will continue to have trouble filling their prescriptions.
While the capacity for Wegovy is gradually increasing, the supply of the lower dose strengths will "remain restricted to safeguard continuity of care," the drugmaker said in its earnings report. A spokesperson for Novo Nordisk told FOX Business that it's specifically "limiting quantities of 0.25 mg, 0.5 mg, and 1 mg dose strengths to wholesalers for distribution to retail pharmacies" to support continuity of care for current patients. Although it's producing and shipping all dose strengths, the company said "demand continues to outpace our increasing production" and that supply disruptions will be ongoing.
Packets of Wegovy move along a conveyor at the Novo Nordisk A/S production facilities in Hillerod, Denmark, on Monday, June 12, 2023.The company told analysts Thursday that there was higher than expected volume growth in recent years for its GLP-1-based products such as Ozempic and Wegovy, which are the same medication – semaglutide. The company said it expects "continued volume growth" but it also admitted that it is dealing with "capacity limitations at some manufacturing sites.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Wegovy-maker Novo Nordisk raises outlook as sales of its weight-loss drug soarThe Danish company's diabetes and obesity division performed particularly well, bolstered by interest in its blockbuster injection Wegovy.
Read more »
Novo Nordisk extends U.S. supply curbs on weight-loss drug WegovyNovo Nordisk will continue to restrict U.S. supplies of starter doses of its hugely popular Wegovy weight-loss drug in the coming quarters, it said on Thursday, as the company struggles to keep up with soaring U.S. demand.
Read more »
Wegovy-maker Novo Nordisk extends curb on supply of weight-loss drug, raises outlookThe Danish drugmaker confirmed that it will continue to restrict the lower-dose strengths of Wegovy as it strives to keep up with demand.
Read more »
Novo Nordisk to acquire obesity drug maker Inversago Pharma for up to $1 billionInversago's drugs use a different approach than most treatments in the obesity and diabetes space.
Read more »
Wegovy weight-loss drugmaker sees profits soarDanish drugmaker Novo Nordisk said it was seeing 'more patients than ever before'.
Read more »
Nearly half of Americans interested in weight-loss drugs like Wegovy, survey findsA KFF health tracking poll found 45% of people are interested in taking a safe and effective weight loss medication
Read more »